Trial · NCT03120949
Results by group690
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 690
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Blood and lymphatic system disorders: Neutropenia | 42 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Blood and lymphatic system disorders: Neutropenia | 57 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Metabolism and nutrition disorders | 113 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Metabolism and nutrition disorders | 135 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Gastrointestinal disorders | 100 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Gastrointestinal disorders | 118 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Injury, poisoning and procedural complications | 101 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Injury, poisoning and procedural complications | 95 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Skin and subcutaneous tissue disorders | 88 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Skin and subcutaneous tissue disorders | 94 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Nervous system disorders | 60 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Nervous system disorders | 81 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Respiratory, thoracic and mediastinal disorders | 60 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Respiratory, thoracic and mediastinal disorders | 68 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Vascular disorders | 60 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Vascular disorders | 68 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | General disorders and administration site conditions | 54 | Participants | |
| Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | General disorders and administration site conditions | 65 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 1: OKZ 64 mg q4w + MTX | Number of Subjects with at Least One SAE | 129 | Participants | |
| Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population) | Treatment Arm 2: OKZ 64 mg q2w + MTX | Number of Subjects with at Least One SAE | 120 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03120949/results?page=2